In advanced NSCLC, particularly in unselected patients, the immunosuppressive TME may be driven by dominant pathways other than TGF‐β, or baseline levels of active TGF‐β might be insufficient for the drug to demonstrate a clear synergistic effect over PD‐L1 inhibition alone. Here, TGFB1 is linked to non-small cell lung carcinoma.